| Title |
Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study
|
| Creator |
Hide Michihiro
Igarashi Atsuyuki
Yagami Akiko
Inomata Naoko
Fukunaga Atsushi
Kaiser Guenther
Wang Junyi
Matsushima Soichiro
Greenberg Steven
Khalil Sam
|
| Source Title |
ALLERGOLOGY INTERNATIONAL
|
| Volume | 67 |
| Issue | 2 |
| Start Page | 243 |
| End Page | 252 |
| Journal Identifire |
ISSN 1323-8930
EISSN 1440-1592
|
| Subjects | |
| Language |
eng
|
| Resource Type | journal article |
| Publisher |
JAPANESE SOCIETY ALLERGOLOGY
|
| Date of Issued | 2018-04 |
| Access Rights | metadata only access |
| Relation |
[DOI] 10.1016/j.alit.2017.10.001
[PMID] 29102514
|
| Remark | This subgroup analysis of the POLARIS study was funded by Novartis Pharmaceuticals. The authors acknowledge the assistance of the investigators, clinical trial staff and participants. The authors also thank Aisling O'Keeffe of Novartis Ireland Ltd., Rukaiyya Khan of Novartis Healthcare Private Limited and Asako Itakura of Novartis K.K. for providing medical writing and editorial assistance, and Lydia Michaut for her professional advice on the bioanalysis methods. The authors acknowledge POLARIS Principal Investigators (Japan): Atsushi Fukunaga; Taizo Hamaguchi; Takaaki Hiragun; Atsuyuki Igarashi; Masami Ikeda; Naoko Inomata; Masafumi Ishibashi; Shusaku Ito; Akiko Kakimi; Atsuko Kato; Satomi Kobayashi; Yumiko Kudo; Akihiro Kume; Ichiro Kurokawa; Yoshihiro Kuwano; Kayoko Matsunaga; Eishin Morita; Hideki Mukai; Hiroshi Murata; Hiromitsu Noguchi; Yuko Nomura; Emiko Sawamura; Yoshihiro Sei; Hideyasu Takata; Katsuhiko Tsukamoto; Takahisa Uchida. |
